NCT03158272View on ClinicalTrials.gov

A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

May 25, 2017

Primary Completion Date

October 23, 2019

Study Completion Date

October 23, 2019

Conditions
Advanced Malignancies
Interventions
BIOLOGICAL

Cabiralizumab

Specified dose on specified days

BIOLOGICAL

Nivolumab

Specified dose on specified days

Trial Locations (4)

1040045

Local Institution, Chuo-ku

2778577

Local Institution, Kashiwa-shi

2968602

Local Institution, Kamogawa-shi

4678602

Local Institution, Nagoya

Sponsors
All Listed Sponsors
collaborator

Ono Pharmaceutical Co. Ltd

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY

NCT03158272 - A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread | Biotech Hunter | Biotech Hunter